HIGHLIGHTS
- who: LENOVO from the Faculty of Pharmacy, Andalas University, Kampus Limau Manis, Padang, West Sumatra, Indonesia have published the research work: Tetraprenyltoluquinone Inhibits the Tumor Marker Aldo-Keto Reductase: An in Silico Study, in the Journal: (JOURNAL)
- what: This study shows that the tetraprenyltoluquinone compound binds to a stronger and more stable ligand than the AKR1B10 inhibitor.
- how: The docking score results showed that the AKR1B10 protein interaction with the test ligand tetraprenyltoluquinone is lower than the native ligand which means the binding energy of tetraprenyltoluquinone to the AKR1B10 (PDB ID 1ZUA) protein . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.